A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Inclusion Criteria:

• Neary et al. Criteria for Frontotemporal Lobar Degeneration
• Age 40 -80
• CDR < 3 or MMSE > 15
• English Speaking
• Study Partner

Exclusion Criteria:

• Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors